Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
Total Valuation
PMV Pharmaceuticals has a market cap or net worth of $66.51M. The enterprise value is -$54.13M.
Market Cap$66.51M
Enterprise Value-$54.13M
Share Statistics
PMV Pharmaceuticals has 53,211,506 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,211,506
Owned by Insiders12.71%
Owned by Institutions52.76%
Financial Efficiency
PMV Pharmaceuticals’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -37.83%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.83%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count47
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PMV Pharmaceuticals is ―. PMV Pharmaceuticals’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio0.44
Price to Fair Value0.44
Price to FCF-1.50
Price to Operating Cash Flow-0.99
PEG Ratio0.06
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of 0.00 and earned -58.71M in profits. Earnings per share was -1.14.
Revenue0.00
Gross Profit-1.14M
Operating Income-85.45M
Pretax Income-74.81M
Net Income-58.71M
EBITDA-73.67M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was -73.05M and capital expenditures -70.00K, giving a free cash flow of -73.12M billion.
Operating Cash Flow-73.05M
Free Cash Flow-73.12M
Free Cash Flow per Share-1.37
Dividends & Yields
PMV Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-19.21%
50-Day Moving Average1.34
200-Day Moving Average1.24
Relative Strength Index (RSI)45.09
Average Volume (3m)263.86K
Important Dates
PMV Pharmaceuticals upcoming earnings date is Mar 4, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend Date―
Financial Position
PMV Pharmaceuticals as a current ratio of 12.22, with Debt / Equity ratio of 0.73%
Current Ratio12.22
Quick Ratio12.22
Debt to Market Cap<0.01
Net Debt to EBITDA0.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PMV Pharmaceuticals has paid -16.10M in taxes.
Income Tax-16.10M
Effective Tax Rate0.22
Enterprise Valuation
PMV Pharmaceuticals EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.74.
EV to Sales0.00
EV to EBITDA-0.52
EV to Free Cash Flow-0.74
EV to Operating Cash Flow-0.74
Balance Sheet
PMV Pharmaceuticals has $129.25M in cash and marketable securities with $931.00K in debt, giving a net cash position of $128.32M billion.
Cash & Marketable Securities$129.25M
Total Debt$931.00K
Net Cash$128.32M
Net Cash Per Share$2.41
Tangible Book Value Per Share$3.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PMV Pharmaceuticals is $5.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.00
Price Target Upside309.84% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-58.47%